DOI QR코드

DOI QR Code

A Case of Hemolytic Uremic Syndrome after Transarterial Chemoembolization with Cisplatin

시스플라틴을 이용한 경동맥 화학색전술 후 발생한 용혈성 요독증후군 1예

  • Yang, Jee Eun (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Kang Mo (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Shim, Ju Hyun (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lim, Young-Suk (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Han Chu (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Chung, Young-Hwa (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Lee, Yung Sang (Division of Gastroenterology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • 양지은 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 김강모 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 심주현 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 임영석 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 이한주 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 정영화 (울산대학교 의과대학 서울아산병원 소화기내과) ;
  • 이영상 (울산대학교 의과대학 서울아산병원 소화기내과)
  • Received : 2012.07.30
  • Accepted : 2012.10.24
  • Published : 2013.07.01

Abstract

Hemolytic uremic syndrome (HUS) is a rare disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. These characteristics are related to the formation of platelet-rich microthrombi in the microvasculature. HUS is associated with a variety of etiologies, including cisplatin. Previously reported HUS cases after cisplatin administration were almost always related to systemic combination chemotherapy that included cisplatin. Transarterial chemoembolization (TACE) is commonly used in treatment of hepatocellular carcinoma, and most centers in Korea use cisplatin. A 70-year-old female with hepatocellular carcinoma was treated with TACE including cisplatin and subsequently developed clinical and laboratory findings compatible with HUS.

Keywords

References

  1. Park HW. Hemolytic uremic syndrome. Korean J Pediatr 2007;50:931-937. https://doi.org/10.3345/kjp.2007.50.10.931
  2. Levi JA, Aroney RS, Dalley DN. Haemolytic anaemia after cisplatin treatment. Br Med J (Clin Res Ed) 1981;282: 2003-2004. https://doi.org/10.1136/bmj.282.6281.2003
  3. Thurnher D, Kletzmayr J, Formanek M, et al. Chemotherapyrelated hemolytic-uremic syndrome following treatment of a carcinoma of the nasopharynx. Oncology 2001;61:143-146. https://doi.org/10.1159/000055365
  4. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-442. https://doi.org/10.1053/jhep.2003.50047
  5. Naiki T, Ishikawa S, Kamisawa H, Kato T, Akita H, Okamura T. Severe hemolytic uremic syndrome associated with cisplatin-based chemotherapy for advanced bladder cancer. J Rural Med 2008;3:37-40. https://doi.org/10.2185/jrm.3.37
  6. Licciardello JT, Moake JL, Rudy CK, Karp DD, Hong WK. Elevated plasma von Willebrand factor levels and arterial occlusive complications associated with cisplatin-based chemotherapy. Oncology 1985;42:296-300. https://doi.org/10.1159/000226049
  7. Maloisel F, Kurtz JE, Andres E, Gorodetsky C, Dufour P, Oberling F. Platin salts‐induced hemolytic anemia: cisplatinand the first case of carboplatin-induced hemolysis. Anticancer Drugs 1995;6:324-326. https://doi.org/10.1097/00001813-199504000-00018
  8. Canpolat C, Pearson P, Jaffe N. Cisplatin-associated hemolytic uremic syndrome. Cancer 1994;74:3059-3062. https://doi.org/10.1002/1097-0142(19941201)74:11<3059::AID-CNCR2820741125>3.0.CO;2-Z
  9. Khansur T, Kennedy A. Case report: cisplatin-induced hemolytic uremic syndrome. Am J Med Sci 1991;301: 390-392. https://doi.org/10.1097/00000441-199106000-00006
  10. Rudnick MR, Berns JS, Cohen RM, Goldfarb S. Nephrotoxic risks of renal angiography: contrast media-associated nephrotoxicity and atheroembolism: a critical review. Am J Kidney Dis 1994;24:713-727. https://doi.org/10.1016/S0272-6386(12)80235-6